Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label PK, safety and tolerability of lumacaftor + ivacaftor in children 6–11 years with cystic fibrosis (F508del homozygous)
2017-001078-41Phase 3
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-001078-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001078-41.